- Home
- PXLW vs BCTX Comparison
PXLW vs BCTX Comparison
Compare PXLW & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- BCTX
- Stock Information
- Founded
- PXLW 1997
- BCTX 2014
- Country
- PXLW United States
- BCTX Canada
- Employees
- PXLW N/A
- BCTX N/A
- Industry
- PXLW Semiconductors
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- PXLW Technology
- BCTX Health Care
- Exchange
- PXLW Nasdaq
- BCTX Nasdaq
- Market Cap
- PXLW 28.1M
- BCTX 23.5M
- IPO Year
- PXLW 2000
- BCTX N/A
- Fundamental
- Price
- PXLW $6.85
- BCTX $2.02
- Analyst Decision
- PXLW Strong Buy
- BCTX Strong Buy
- Analyst Count
- PXLW 2
- BCTX 1
- Target Price
- PXLW $15.00
- BCTX $32.00
- AVG Volume (30 Days)
- PXLW 75.2K
- BCTX 995.1K
- Earning Date
- PXLW 08-06-2025
- BCTX 06-16-2025
- Dividend Yield
- PXLW N/A
- BCTX N/A
- EPS Growth
- PXLW N/A
- BCTX N/A
- EPS
- PXLW N/A
- BCTX N/A
- Revenue
- PXLW $34,246,000.00
- BCTX N/A
- Revenue This Year
- PXLW $5.21
- BCTX N/A
- Revenue Next Year
- PXLW $35.68
- BCTX N/A
- P/E Ratio
- PXLW N/A
- BCTX N/A
- Revenue Growth
- PXLW N/A
- BCTX N/A
- 52 Week Low
- PXLW $4.67
- BCTX $1.97
- 52 Week High
- PXLW $14.16
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- PXLW 51.29
- BCTX 22.76
- Support Level
- PXLW $7.01
- BCTX $1.97
- Resistance Level
- PXLW $7.56
- BCTX $3.00
- Average True Range (ATR)
- PXLW 0.75
- BCTX 0.19
- MACD
- PXLW -0.02
- BCTX -0.09
- Stochastic Oscillator
- PXLW 5.37
- BCTX 4.20
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.